310
Participants
Start Date
January 31, 2010
Primary Completion Date
June 30, 2023
Study Completion Date
December 31, 2029
Carboplatin and Paclitaxel
Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
Doxorubicin, cyclophosphamide
Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
Medisch Centrum Alkmaar, Alkmaar
NKI-AVL, Amsterdam
OLVG, Amsterdam
Reinier de Graaf Groep, Delft
Deventer Ziekenhuis, Deventer
Albert Schweitzer ziekenhuis, Dordrecht
Ziekenhuis Gelderse Vallei, Ede
Kennemer Gasthuis, Haarlem
Atrium Medisch Centrum Parkstad, Heerlen
Spaarne Ziekenhuis, Hoofddorp
LUMC, Leiden
Maasstad ziekenhuis, Rotterdam
Medisch Centrum Haaglanden, The Hague
Isala Klinieken, Zwolle
The Netherlands Cancer Institute
OTHER